X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

    Continuous Bioprocessing Market to Surge by 2028

    Advancing Asia-Pacific Healthcare & Biopharma Innovation

    Generative AI in Pharma: Opportunities & Challenges

    Global Biopharma Market to Hit $566B by 2032

    AI Boosts Small Molecule Therapies for I&I Diseases

    Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

    Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

    Continuous Bioprocessing Market to Surge by 2028

    Advancing Asia-Pacific Healthcare & Biopharma Innovation

    Generative AI in Pharma: Opportunities & Challenges

    Global Biopharma Market to Hit $566B by 2032

    AI Boosts Small Molecule Therapies for I&I Diseases

    Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

    Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Boehringer Ingelheim achieves major breakthrough in canine cardiology

Yuvraj_pawp by Yuvraj_pawp
30th October 2017
in Research & Development

Dogs suffering from cardiovascular disease and related clinical signs will officially have an opportunity for a better and longer life, according to significant research undertaken by Boehringer Ingelheim as part of its global EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) study.

The study found that pimobendan (Vetmedin®) can postpone the onset of clinical signs of Myxomatous Mitral Valve Disease (MMVD) by a median of 15 months, thereby significantly improving the quality of life of affected dogs. Led by independent cardiologists at 36 specialist veterinary cardiac investigative centers in 11 countries, the EPIC study is the largest-ever worldwide cardiac study in pet dogs.

In the preclinical phase no signs of the condition are visible to the dog owners; however, the underlying disease progression is irreversible. The findings will enable dogs suffering from MMVD to be identified in the preclinical stage and treated before symptoms emerge, transforming the diagnosis and management of the condition. This will deliver unprecedented benefits to pets and their owners affected by the most common form of canine heart disease.

The key findings include:
60% more time in preclinical stage (ACVIM Class B2) of heart disease*
A 15-month delay in time to composite primary endpoint compared with dogs receiving placebo*
This equals 10% more life without signs of congestive heart failure which impact quality of life or cardiac-related death+
Dr. Joachim Hasenmaier, Board of Managing Directors, responsible for Corporate Board Division Animal Health
Dr Joachim Hasenmaier

Dr Joachim Hasenmaier, Head of the Animal Health Business Unit and Member of the Board of Managing Directors at Boehringer Ingelheim, said: “It is exceptionally rare for any veterinary product to offer such life-changing benefits to dogs and their owners, and this five-year study provides a real opportunity for not only improvement to quality of life, but also an increased life expectancy.”

“We are immensely proud of this research, which demonstrates our ongoing commitment to preventive care.”

Characterised by a heart murmur, MMVD is the most prevalent form of heart disease globally which affects up to 7.5% of all dogs and significantly more in those dogs at higher risk which are typically the smaller breeds. However, it typically takes several years for outward clinical signs to appear, during which time the condition is left to worsen undetected.

Professor Jens Häggström, lead investigator of the EPIC trial, from the Swedish University of Agricultural Sciences, Uppsala, said: “The conclusions from this study will transform the way we approach our response to heart murmurs. Vets no longer have to adopt a ‘watch and wait’ approach when dealing with suspected cases of heart disease. For the first time, veterinary professionals will be equipped to combat MMVD earlier, improving a dog’s quality of life by delaying the onset of clinical signs such as coughing, difficulties in breathing and exercise intolerance.“

Pimobendan (Vetmedin®) is already authorised in all major veterinary markets and is the world’s best-selling medication for the treatment of congestive heart failure in dogs. It is the only recommended treatment for preclinical heart disease in the Consensus Statement on heart disease management of the American College of Veterinary Internal Medicine (ACVIM) (presented at the ACVIM Congress, Washington, 2017). Vetmedin® received recommendation for approval of the new indication from the Reference Member State on behalf of the European countries in July 2017. Countries that have nationally approved the EPIC claim include Germany, Spain, Portugal, Italy, UK, France and Denmark.

Further countries outside the European Union who have already approved the new indication include Australia, New Zealand and South Africa.

The results of the study can be found on the EPIC trial website under http://www.results.epictrial.com/ (link is external), or on the Journal of Veterinary Internal Medicine (JVIM) website under https://www.ncbi.nlm.nih.gov/pubmed/27678080

About Boehringer Ingelheim Animal Health
As the second largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.

Boehringer Ingelheim
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com

 

Previous Post

Enterome completes first phase 1 study of EB8018 to treat Crohn’s disease

Next Post

Eisai To Present Latest Data At 10th Clinical Trials On Alzheimer’s Diesase

Related Posts

Drug Development

Continuous Bioprocessing Market to Surge by 2028

7th March 2025
Insights

Advancing Asia-Pacific Healthcare & Biopharma Innovation

7th March 2025
Insights

Generative AI in Pharma: Opportunities & Challenges

7th March 2025
Drug Development

Global Biopharma Market to Hit $566B by 2032

7th March 2025
Clario joins forces with Mobilise-D to advance Digital Mobility Outcomes in clinical trials
News

Detect-ION and Moffitt Cancer Center Collaborate to Revolutionize Lung Cancer Early Detection

19th August 2024
News

Scaling Cell And Gene Therapies: Challenges And Solutions

11th August 2024
Next Post

Lupus Research Alliance LuCIN Clinical Trials Network Launches Inaugural Studies

Please login to join discussion

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In